Conduit Pharmaceuticals (CDT) announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a ...
Source LinkConduit Pharmaceuticals (CDT) announces the filing of two new patent applications relating to its lead clinical candidate, AZD1656, a HK-4 glucokinase activator licensed from AstraZeneca targeting a ...
Source Link
Comments